Hani Sabbour graduated with a Bachelors Degree in basic Medical Sciences and a Bachelors Degree in Medicine and Surgery from Kuwait University. Faculty of Medicine in 1994 with first class honors and was twice awarded His Highness the Emirs Gold Medal for academic excellence in both degrees. He subsequently went on to train in Internal Medicine and Cardiovascular Disease at SUNY Stony Brook in New York and was elected resident and fellow of the year several times. He completed his training in Clinical Cardiac Electrophysiology at the Massachusetts General Hospital. Harvard Medical School and was appointed Clinical Instructor in Cardiology at Harvard Medical School in 2001 as well as SUNY Stony Brook.
Dr. Sabbour is currently American Board of Internal Medicine Certified in Advanced Heart failure and Transplant Cardiology. Internal Medicine. Cardiology. Electrophysiology. and Board Certified in Echocardiography and Nuclear Cardiology. He has always been heavily involved in teaching and been on the teaching faculty at Brown University since 2006. He was recently promoted to Clinical Assistant Professor of Medicine and Cardiology at Brown University Warren Alpert School of Medicine. Dr Sabbour has been active in research and is currently an active PI in two international multicentre trials in the field of pacing and ICDs and has had several publications in the field. He was also appointed the Internal medicine residency program director at Al Ain Hospital as well as Arab Board Cardiology fellowship site director . He has been in practice in Rhode Island for 11 years and recently moved to the UAE to be on staff as Consultant Cardiologist at SKMC. Mafraq Hospital. Al Ain Hospital and Tawam Hospital. His main clinical interests are the management of Arrhythmias and Advanced CHF and Pulmonary HTN as well as Familial Hyperlipidemia cardiac imaging.
Dr.Sabbour is currently a member of the Guideline Writing Group for HOFH in the Gulf and is participating in the design of a clinical education screening program for FH in Abu Dhabi. UAE as well as utilization of therapeutic plasmapheresis in FH patients having initiated plasmapheresis on the only documented HOFH patient receiving this therapy in UAE. He is currently leading and supervising an ongoing resident audit study of FH within SEHA to assess the unusually increased prevalence of FH in patient using LDL criteria.